BRAF and metastatic neoplasm: Systemic therapy with immune checkpoint inhibitors or combined BRAF/MEK-targeted therapy is recommended by international guidelines for patients with resected stage IIB to IV melanoma, as well as for those with unresectable or metastatic disease (65, 66).